By Iain Gilbert
Date: Wednesday 04 Feb 2026
(Sharecast News) - Gene and cell therapy company Oxford Biomedica said on Wednesday that it has expanded its strategic partnership with Bristol Myers Squibb, inking a new commercial supply agreement for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.
| Form 8.3 NCC GROUP PLC | 09-Feb-2026 | 12:09 | RNS |
| Form 8.5 (EPT/RI) NCC Group PLC | 09-Feb-2026 | 12:00 | RNS |
| Form 8.3 NCC Group Plc | 09-Feb-2026 | 11:57 | RNS |
| Form 8.3 - NCC Group PLC | 09-Feb-2026 | 11:56 | RNS |
| Form 8.3 NCC Group plc | 09-Feb-2026 | 11:46 | RNS |
| Questor:Meggitt | 23-Dec-2014 | Telegraph |
| Questor :Ricardo | 31-Oct-2014 | Telegraph |
| Questor:CSR | 17-Oct-2014 | Telegraph |
| Questor:BAE Systems | 03-Sep-2014 | Telegraph |
| Questor :Sage Group | 09-May-2014 | Telegraph |
| Price | 8,524.02 |
| Change Today | 78.82 |
| % Change | 0.93 % |
| 06-Feb-26 Close | 8,445.20 |
You are here: research